Nyxoah SA (NYXH)
NGM · Healthcare · Medical Devices
$0.89
-1.34%
Closing price as of 2026-10-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$90.4M
Shares Outstanding
101.8M
P/S (TTM)
3.7x
Exchange
NGM
Currency
USD
About Nyxoah SA
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Quarterly Financials (EUR)
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 2.0M | 5.6M | 6.4M | 7.7M |
| Gross Profit | 1.2M | 3.6M | 3.6M | 4.6M |
| Operating Income | (24.2M) | (18.3M) | (20.5M) | (20.5M) |
| Net Income | (23.6M) | (23.5M) | (15.9M) | (33.0M) |
| Diluted EPS | (EUR 0.63) | (EUR 0.59) | (EUR 0.37) | (EUR 0.58) |
Annual Financials (EUR)
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 3.1M | 4.3M | 4.5M | 10.0M |
| Gross Profit | 1.9M | 2.7M | 3.0M | 6.3M |
| Operating Income | (32.5M) | (45.1M) | (58.8M) | (82.9M) |
| Net Income | (31.2M) | (43.2M) | (59.2M) | (90.1M) |
| Diluted EPS | (EUR 1.21) | (EUR 1.54) | (EUR 1.81) | (EUR 2.36) |